Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies (PTNT)
OTHER OTC:PTNT
PTNT Stock Chart & Stats
$5.88
--
Market closed
$5.88
--
Day’s Range― - ―
52-Week Range$1.77 - $72.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$5.72M
Enterprise Value$4.11M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding973,291
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Palatin Technologies News
PTNT FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $1.77 and its highest was $72.50 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $5.72M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 17, 2025 which is in 12 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on Oct 07, 2025. The company reported -$2.398 earnings per share for the quarter, beating the consensus estimate of -$9.5 by $7.102.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Overvalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 973,291 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$2.398 in its last earnings report, beating expectations of -$9.5. Following the earnings report the stock price went down -7.975%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTNT
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Technical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―